Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole

Clinical Pharmacokinetics

Volumn 47, Issue 8, 2008, Pages 533-542

  Mallikaarjun, Suresh ^a   Shoaf, Susan E ^a   Boulton, David W ^b   Bramer, Steven L ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antipsychotics, pharmacokinetics; Aripiprazole, pharmacokinetics; Liver dysfunction; Renal impairment

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; OPC 14714; OPC 3373; SPIRONOLACTONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; CREATININE CLEARANCE; DEATH; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; FEMALE; HUMAN; KIDNEY FAILURE; LIVER BLOOD FLOW; LIVER FAILURE; MALE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; VITAL SIGN; VOMITING;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; FEMALE; HUMANS; KIDNEY DISEASES; LIVER DISEASES; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN BINDING; QUINOLONES; SEVERITY OF ILLNESS INDEX;

EID: 47049096318     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847080-00003     Document Type: Article

References (19)

1. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60 (7): 681-90
2. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61 (2-3): 123-36
3. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63 (9): 763-71
4. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6 (4): 325-37
5. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005; 187 (9): 235-42
6. Keck Jr PE, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160 (9): 1651-8
7. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20 (4): 536-46
8. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302 (1): 381-9
9. Inoue T, Domae M, Yamada K, et al. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)- quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 1996; 277 (1): 137-43
10. Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-dichlorophenyl)-1- piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995; 274 (1): 329-36
11. Kane J, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo [abstract]. Schizophr Res 2000; 41 (Special Issue): 39
12. Bristol-Myers Squibb Company/Otsuka America Pharmaceutical, Inc. Aripiprazole (Abilify) prescribing information. Princeton (NJ): Bristol-Myers Squibb Co. & Otsuka America Pharmaceutical, Inc., 2006
13. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004; 44 (2): 179-87
14. US FDA. Code of federal regulations, title 21 - food and drugs: chapter I - Food and Drug Administration, Department of Health and Human Services. Part 56: institutional review boards [online]. Available from URL: http://www.access.gpo.gov/nara/cfr/waisidx_07/21cfrv1_07.html [Accessed 2008 May 23]
15. US FDA. Code of federal regulations, title 21 - food and drugs: chapter I - Food and Drug Administration, Department of Health and Human Services. Part 50: protection of human subjects [online]. Available from URL: http://www.access.gpo.gov/nara/cfr/waisidx_07/21cfrv1_07.html [Accessed 2008 May 23]
16. Albers I, Hartmann H, Bircher J, et al. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989; 24 (3): 269-76
17. Kubo M, Mizooku Y, Hirao Y, et al. Development and validation of an LC-MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 822 (1-2): 294-9
18. Jusko W. Guidelines for collection and analysis of pharmacokinetic data. In: Evans W, Jusko W, Schentag J, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver (WA): Applied Therapeutics, 1992: 1-43
19. Dalen P, Dahl ML, Eichelbaum M, et al. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics 1999; 9 (6): 697-706